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The molecular mechanisms that link obesity and insulin resis-
tance have not been completely understood yet and are subject
of intensive research. Growing evidence suggests that obesity,
insulin resistance, and type 2 diabetes mellitus (T2DM) are accom-
panied by a state of subclinical inﬂammation [1]. Thus, elevated
serum concentrations and adipose tissue expression of proinﬂam-
matory tumor necrosis factor (TNF) a and interleukin (IL)-6 are
found in insulin resistant and obese patients, as well as in subjects
with T2DM [2–4]. Both cytokines are able to potently induce insu-
lin resistance in adipocytes in vitro [5,6].
Recently, IL-1ß has been characterized as a novel fat-derived
adipokine with insulin resistance-inducing and proinﬂammatory
properties [7–9]. Thus, chronic IL-1ß treatment impaired insulin-chemical Societies. Published by E
m cell-derived adipocytes; IL,
d protein; NF, nuclear factor;
llitus; TIARP/STAMP2, tumor
x-transmembrane protein of
ipzig.de (M. Fasshauer).induced glucose transporter (GLUT)-4 translocation to the plasma
membrane through down-regulation of insulin receptor sub-
strate-1 [7]. Long-term IL-1a stimulation of 3T3-L1 adipocytes in-
duced suppressor of cytokine signaling (SOCS)-1 and -3 [10] which
are well-established inhibitors of insulin signal transduction [11].
IL-1ß dramatically reduced production of the insulin-sensitizing
adipokine adiponectin in 3T3-L1 adipocytes and in human primary
adipocytes [8]. Consistent with these ﬁndings, IL-1 receptor (IL-
1R)-deﬁcient non-obese diabetic mice developed diabetes mellitus
signiﬁcantly slower than control mice [12]. Larsen and co-workers
have shown that blockage of IL-1 signaling with anakinra, a recom-
binant human IL-1R antagonist, improved glycemic control in pa-
tients with T2DM most likely through improved secretory
function of b-cells [13]. Interestingly, IL-1ß mRNA is upregulated
in adipose tissue of insulin resistant animal models such as lep-
tin-deﬁcient ob/ob mice and mice on high-fat diet [8]. We have re-
cently demonstrated that IL-1ß is a potent inductor of insulin
resistance-associated circulating proteins including lipocalin-2,
serum amyloid A3, and tissue inhibitor of metalloproteinase-1 in
murine adipocytes in vitro [14–16].
Taking these studies into consideration, identiﬁcation and char-
acterization of downstream signaling molecules of TNFa and IL-6
but also of IL-1ß in adipocytes has become a focus of currentlsevier B.V. All rights reserved.
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obesity and associated diseases including insulin resistance,
T2DM, and hypertension might be derived from these studies. In
2001, Moldes and co-workers showed convincingly that TNFa-in-
duced adipose-related protein (TIARP) [17], also known as six-
transmembrane protein of prostate 2 (STAMP2) [18] is induced by
TNFa in a dose- and time-dependent fashion in adipocytes and dur-
ing adipogenic remodeling [17]. Studies with TIARP/STAMP2-deﬁ-
cient mice indicate that this protein participates in integrating
inﬂammatory and metabolic response [19]. Our group has shown
that TIARP/STAMP2 is not only upregulated by TNFa but also IL-6
and growth hormone (GH) in murine adipocytes [20,21]. However,
a potential regulation of TIARP/STAMP2 by IL-1ß has not been elu-
cidated so far. In the current study, we, therefore, examined the ef-
fect of IL-1ß on TIARP/STAMP2 synthesis in vitro.
2. Materials and methods
2.1. Materials
Dexamethasone, IL-1ß, IL-6, indomethacine, isobutylmethyl-
xanthine, and TNFa were obtained from Sigma–Aldrich (Taufkir-
chen, Germany). AG490, isobutylmethylxanthine, LY294002,
parthenolide, and PD98059 were obtained from Calbiochem (Bad
Soden, Germany), insulin from Roche Molecular Biochemicals
(Mannheim, Germany), and troglitazone from Alexis Biochemicals
(Lörrach, Germany). Cell culture reagents were purchased from
PAA (Pasching, Austria), oligonucleotides from MWG-Biotech
(Ebersberg, Germany). Rabbit anti-human TIARP/STAMP2 antibody
was obtained from ProteinTech Group Inc. (Chicago, USA).
2.2. Cell culture and differentiation
3T3-L1 cells (American Type Culture Collection, Rockville, MD)
were grown and differentiated into adipocytes as previously
described [22]. In brief, preadipocytes were grown to conﬂuence
in DMEM containing 25 mM glucose (DMEM-HG), 10% fetal bovine
serum, and antibiotics (culture medium). Conﬂuent cells were
induced for 3 days in culture medium further supplemented with
1 lM insulin, 0.5 mM isobutylmethylxanthine, and 0.1 lM dexa-
methasone before they were maintained for another 3 days in cul-
ture medium with 1 lM insulin and for additional 4–8 days in
culture medium. After this period, more than 90% of the cells
showed fat droplet accumulation.
Human mesenchymal stem cell-derived adipocytes (hMSC-Ad)
were obtained by differentiation of human mesenchymal stem
cells (hMSCs). HMSCs were purchased from Lonza (Verviers, Bel-
gium) and were cultured in mesenchymal stem cell medium
(PAA, Pasching, Austria). All experiments with hMSCs were per-
formed between passages 8 and 12. Cells were seeded in 6 cm
plates and maintained in mesenchymal stem cell medium until
conﬂuence. Conﬂuent hMSCs were cultured in differentiation med-
ium containing DMEM-HG, 10% fetal bovine serum, 1% penicillin/
streptomycin, 1% amino acids solution, 2 lg/ml dexamethasone,
200 lM indomethacine, 0.5 mM isobutylmethylxanthine, 1 lM
insulin, and 10 lM troglitazone. After three weeks in differentia-
tion medium, more than 90% of the cells had accumulated fat drop-
lets and these hMSC-Ad were used to elucidate the inﬂuence of IL-
1ß on TIARP/STAMP2 mRNA and protein synthesis.
All stimulation experiments were carried out in DMEM-HG
without any additions. Serum deprivation periods before effector
addition were in the range between 5 h and 16 h. It has to be noted
in this context that in our hands a serum deprivation period be-
tween 5 h and 16 h did not signiﬁcantly inﬂuence hormone-modu-
lated gene expression in 3T3-L1 adipocytes in previous
experiments (data not shown).2.3. Analysis of TIARP/STAMP2 mRNA production
TIARP/STAMP2 mRNA synthesis was determined by quantita-
tive real-time RT-PCR in a ﬂuorescent temperature cycler (ABI
Prism 7000, Applied Biosystems, Darmstadt, Germany) as de-
scribed previously [20,21]. Brieﬂy, total RNA was isolated from
3T3-L1 adipocytes with TRIzol reagent (Invitrogen, Life Technolo-
gies Inc., Carlsbad, CA) or from hMSC-Ad with Invisorb Spin Cell
RNA Mini Kit (Invitek, Berlin, Germany) according to the manufac-
turers´ instructions. One microgram RNA was reverse transcribed
using standard reagents (Invitrogen, Life Technologies Inc., Carls-
bad, CA). Two microliters of each RT reaction was ampliﬁed in a
26 ll PCR. After initial denaturation at 95 C for 10 min, 40 PCR cy-
cles were performed using the following conditions: 95 C for 15 s,
60 C for 1 min, and 72 C for 1 min. The following primer pairs
were used: mTIARP/STAMP2 (Accession no. AJ319746) TAG-
GGTGTAGGCGAGCAGCAGT (sense) and TCAGTGACACGCGGGAAG-
ATT (antisense); hTIARP/STAMP2 (Accession no. NM024636)
GCTGGCATGTAATTCTTCCTCTAT (sense) and TCCCTCCATTTTTATT-
CAGTCTTT (antisense); m36B4 (Accession no. NM007475)
AAGCGCGTCCTGGCATTGTCT (sense) and CCGCAGGGGCAG-
CAGTGGT (antisense); h18sRNA (Accession no. NR_003286) GAC-
AACAAGCTCCGTGAAGAC (sense) and ATTAACAGACAAGGCC
TACAGACT (antisense). SYBR Green I ﬂuorescence emissions were
monitored after each cycle and synthesis of TIARP/STAMP2, 36B4,
and 18sRNA mRNA was quantiﬁed using the second derivative
maximummethod of the ABI Prism 7000 software (Applied Biosys-
tems, Darmstadt, Germany). This method determines the crossing
points of individual samples by an algorithm identifying the ﬁrst
turning point of the ﬂuorescence curve. TIARP/STAMP2 expression
was calculated relative to 36B4 (3T3-L1 cells) or 18sRNA (hMSC-
Ad) which were used as internal controls due to their resistance
to hormonal regulation [23,24]. Speciﬁc transcripts were con-
ﬁrmed by melting curve proﬁles (cooling the sample to 68 C and
heating slowly to 95 C with measurement of ﬂuorescence) at the
end of each PCR and the speciﬁcity of the PCR was further veriﬁed
by subjecting the ampliﬁcation products to agarose gel
electrophoresis.2.4. Analysis of TIARP/STAMP2 protein synthesis
For isolation of the membrane fraction, hMSC-Ad were har-
vested in ice-cold lysis buffer I (20 mM HEPES, pH 7.4, 1 mM EDTA,
250 mM sucrose, protease inhibitor mixture) and disrupted in a
Dounce homogenizer (20 strokes). Cell extracts were centrifuged
at 3000g for 10 min and supernatants were further centrifuged
at 30000g for 1 h. Pellets were resolved in lysis buffer II with
protease inhibitor mixture as described previously [25]. Detection
of TIARP/STAMP2 synthesis by Western blotting was performed
essentially as described [25]. Brieﬂy, equal amounts of hMSC-Ad
membrane fractions were directly solubilized in Laemmli sample
buffer, boiled for 3 min, separated by 12% SDS–PAGE, and
transferred to nitrocellulose membranes. Membranes were
blocked in Tris buffered saline (10 mM Tris, 150 mM NaCl, 0.05%
Tween, pH 7.2) containing 3% delipidated milk for 30 min and
incubated with TIARP/STAMP2 antibody overnight at 4 C. Specif-
ically bound primary antibodies were detected with enhanced
chemiluminescence.
2.5. Statistical analysis
Results are expressed as mean ± S.E. Differences between vari-
ous cell treatments were analysed by unpaired Student’s t-tests.
P values < 0.01 are considered highly signiﬁcant, <0.05 are consid-
ered signiﬁcant.
1198 S. Kralisch et al. / FEBS Letters 583 (2009) 1196–12003. Results
3.1. IL-1ß stimulates TIARP/STAMP2 mRNA in 3T3-L1 cells
IL-1ß stimulated TIARP/STAMP2 gene expression in a dose-
dependent fashion. Thus, a signiﬁcant 2.6-fold induction of
TIARP/STAMP2 mRNA synthesis was detectable at IL-1ß concentra-
tions as low as 0.02 ng/ml (P < 0.01) (Fig. 1A). A maximal 9.2-fold
increase was found at 20 ng/ml of the cytokine (P < 0.01)
(Fig. 1A). Furthermore, 20 ng/ml IL-1ß upregulated TIARP/STAMP2
mRNA time-dependently with signiﬁcant maximal 18.6-fold stim-
ulation detectable 8 h after effector addition (P < 0.05) (Fig. 1B) and
upregulation persisting signiﬁcantly for up to 24 h (P < 0.01)0
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Fig. 1. Dose- and time-dependent stimulation of TIARP/STAMP2 gene expression by
IL-1ß in 3T3-L1 cells. (A) Fully differentiated 3T3-L1 adipocytes were serum-starved
for 6 h before the indicated concentrations of IL-1ß were added for 16 h. (B) Fully
differentiated 3T3-L1 adipocytes or (C) 3T3-L1 preadipocytes were serum-starved
overnight before 20 ng/ml IL-1ß was added for the indicated periods of time. Total
RNA was extracted and subjected to quantitative real-time RT-PCR to determine
TIARP/STAMP2 mRNA production normalized to 36D4 levels as described in Section
2. Data are expressed relative to untreated control cells (=100%). Results are the
means ± S.E. of (A,B) seven and (C) three independent experiments.  Denotes
P < 0.01,  denotes P < 0.05 comparing IL-1ß-treated with non-treated cells.(Fig. 1B). Similar to the results obtained in differentiated adipo-
cytes, 20 ng/ml IL-1ß signiﬁcantly induced TIARP/STAMP2 mRNA
synthesis time-dependently in non-differentiated 3T3-L1 cells
with maximal 10.8-fold (P < 0.05) stimulation seen after 8 h of
treatment (Fig. 1C).
3.2. Jak2, NFjB, and p44/42 mitogen-activated protein (MAP) kinase
mediate induction of TIARP/STAMP2 expression by IL-1ß
We elucidated which signaling molecules might mediate the
positive effect of IL-1ß on TIARP/STAMP2 expression. To this end,
3T3-L1 adipocytes were pretreated with speciﬁc pharmacological
inhibitors of Jak2 (AG490, 10 lM), NFjB (parthenolide, 50 lM),
p44/42 MAP kinase (PD98059, 50 lM), or phosphatidylinositol
(PI) 3-kinase (LY294002, 10 lM) for 1 h before IL-1ß (20 ng/ml)
was added for 16 h. Treatment of 3T3-L1 adipocytes with AG490
for 17 h signiﬁcantly suppressed basal TIARP/STAMP2 expression
to 20% of control levels (P < 0.01) (Fig. 2). Similarly, the NFjB inhib-
itor parthenolide and the p44/42 MAP kinase inhibitor PD98059
signiﬁcantly suppressed basal TIARP/STAMP2 expression to 33%
and 49% of control levels, respectively (P < 0.01) (Fig. 2). In con-
trast, treatment of 3T3-L1 adipocytes with the PI 3-kinase inhibitor
LY294002 for 17 h did not signiﬁcantly inﬂuence basal TIARP/
STAMP2 mRNA synthesis (Fig. 2). Again, TIARP/STAMP2 expression
was increased more than 15-fold after 16 h of IL-1ß treatment
(P < 0.01) (Fig. 2). This induction was completely reversed to 93%
of control levels in cells pretreated with the Jak2 inhibitor AG490
(P < 0.01) (Fig. 2). Similarly, IL-1ß-induced TIARP/STAMP2 mRNA
induction was completely blocked to 63% of untreated controls
after pharmacological inhibition of NFjB by parthenolide
(P < 0.01) (Fig. 2). Furthermore, inhibition of p44/42 MAP kinase
by PD98059 signiﬁcantly and partially reversed IL-1ß-induced
TIARP/STAMP2 mRNA synthesis by almost 60% (P < 0.05) (Fig. 2).
In contrast, LY294002 treatment did not signiﬁcantly inﬂuence
IL-1ß-induced TIARP/STAMP2 expression (Fig. 2).
3.3. Synergistic effects of maximally effective concentrations of IL-1ß,
TNFa, and IL-6 on TIARP/STAMP2 mRNA expression
We tested whether maximally effective concentrations of IL-1ß,
TNFa, and IL-6 might inﬂuence TIARP/STAMP2mRNA expression in0
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Fig. 2. IL-1ß-induced TIARP/STAMP2 mRNA expression is mediated via Jak2, NFjB,
and p44/42 MAP kinase. After serum starvation for 5 h, 3T3-L1 adipocytes were
maintained in the presence or absence of AG490 (AG, 10 lM), parthenolide (Part,
50 lM), PD98059 (PD, 50 lM), or LY294002 (LY, 10 lM) for 1 h before IL-1ß (20 ng/
ml) was added for 16 h. After extraction of total RNA, quantitative real-time RT-PCR
was performed as described in Section 2. TIARP/STAMP2 gene expression normal-
ized to 36B4 is given relative to untreated control cells (Con = 100%; ----). Results
are the means ± S.E. of seven independent experiments.  Denotes P < 0.01, 
denotes P < 0.05 comparing untreated with inhibitor-pretreated or IL-1ß-treated
cells, as well as comparing IL-1ß-treated with inhibitor-pretreated adipocytes.
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Fig. 3. Maximally effective concentrations of IL-1ß, TNFa, and IL-6 induce TIARP/
STAMP2 mRNA synergistically. After overnight serum starvation, 3T3-L1 adipocytes
were cultured in the presence or absence of IL-1ß (20 ng/ml), TNFa (20 ng/ml), and
IL-6 (30 ng/ml) for 8 h. Total RNA was extracted and subjected to quantitative real-
time RT-PCR to determine TIARP/STAMP2 normalized to 36D4 as described in
Section 2. Data are expressed relative to non-treated control cells (=100%; ----).
Results are the means ± S.E. of three independent experiments.  Denotes P < 0.01,
 denotes P < 0.05 comparing effector-treated with untreated cells.
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S. Kralisch et al. / FEBS Letters 583 (2009) 1196–1200 11993T3-L1 adipocytes synergistically. As shown in Fig. 3, 8 h treatment
with IL-1ß (20 ng/ml), TNFa (20 ng/ml), or IL-6 (30 ng/ml) induced
TIARP/STAMP2 mRNA expression nearly 10-fold (P < 0.05), 5-fold
(P < 0.01), and 4-fold (P < 0.05), respectively. Interestingly, TIARP/
STAMP2 gene expression further increased when 3T3-L1 cells were
treated with IL-1ß and TNFa, IL-1ß and IL-6, or TNFa and IL-6
(Fig. 3). Maximal 33-fold (P < 0.01) induction of TIARP/STAMP2
mRNA was found after treatment of 3T3-L1 adipocytes with the
three cytokines combined (Fig. 3).
3.4. IL-1ß stimulates TIARP/STAMP2 mRNA and protein synthesis in
hMSC-Ad
IL-1ß (20 ng/ml) upregulated TIARP/STAMP2 mRNA time-
dependently in hMSC-Ad with signiﬁcant maximal 16.4-fold stim-
ulation detectable 24 h after effector addition (P < 0.01) (Fig. 4A).
Furthermore, IL-1ß (20 ng/ml) induced TIARP/STAMP2 protein syn-
thesis in these cells after 24 h and 48 h of treatment as compared
to control conditions in two independent experiments (Fig. 4B).
4. Discussion
In the current study, we show for the ﬁrst time that IL-1ß in-
duces TIARP/STAMP2 expression in adipocytes in vitro. In 2001,
TIARP/STAMP2 has been identiﬁed as a TNFa response gene that
is dramatically induced during adipocyte differentiation in mouse
cells [17]. Studies with TIARP/STAMP2-knockout animals indicate
that this protein participates in integrating inﬂammatory and met-
abolic responses [19]. Thus, TIARP/STAMP2-deﬁciency in mice
leads to overt inﬂammation and development of spontaneous met-
abolic disease on a regular diet characterized by insulin resistance,
glucose intolerance, mild hyperglycemia, dyslipidemia, and fatty li-
ver disease [19]. Interestingly, adipose tissue of TIARP/STAMP2-
deﬁcient rodents exhibits elevated expression of inﬂammatory
genes including IL-6, monocyte chemoattractant protein-1, SOCS-
3, and TNFa [19]. Furthermore, accumulation of mononuclear cells
and oxidative stress are increased in adipose tissue of TIARP/
STAMP2-knockout animals [19]. Interestingly, TIARP/STAMP2-
knockdown experiments in 3T3-L1 adipocytes further support
the notion that TIARP/STAMP2 might have an anti-inﬂammatoryfunction. Thus, TIARP/STAMP2-knockdown by speciﬁc siRNA leads
to increased TNFa- and high-glucose-induced IL-6 mRNA expres-
sion as compared to control fat cells. Furthermore, siRNA-mediated
TIARP/STAMP2-deﬁciency causes signiﬁcant impairment of insulin
receptor signaling, as well as insulin-induced glucose uptake and
GLUT-4 translocation [19]. Taking these results into consideration,
it appears plausible that upregulation of TIARP/STAMP2 by IL-1ß
might represent a protective mechanism by which IL-1ß-induced
insulin resistance and proinﬂammatory response is limited in adi-
pocytes in vitro. Since TNFa and IL-6 also stimulate TIARP/STAMP2
expression in 3T3-L1 adipocytes besides IL-1ß [17,21], upregula-
tion of TIARP/STAMP2 might represent a major pathway to protect
excessive insulin resistance and inﬂammation. Interestingly,
TIARP/STAMP2 gene expression further increases when 3T3-L1
cells are treated with maximally effective concentrations of IL-1ß
and TNFa, IL-1ß and IL-6, or TNFa and IL-6. Furthermore, maximal
induction of TIARP/STAMP2 mRNA is found after treatment with
the three cytokines combined. These results indicate that the pro-
inﬂammatory cytokines tested have synergistic effects.
We demonstrate that IL-1ß induces TIARP/STAMP2 protein syn-
thesis in a human adipocyte cell model, i.e. hMSC-Ad. TIARP/
STAMP2 protein synthesis has been assessed in human adipocytes
in the current study since there is no commercial antibody avail-
able against mouse TIARP/STAMP2. Furthermore, TIARP/STAMP2
mRNA expression in hMSC-Ad is induced by IL-1ß in a time-depen-
dent fashion. These results indicate that IL-1b-induced TIARP/
STAMP2 mRNA synthesis is accompanied by stimulated TIARP/
STAMP2 protein production. Furthermore, our results support the
notion that IL-1ß is a principal positive regulator of TIARP/STAMP2
expression in both human and mouse fat cells in vitro.
1200 S. Kralisch et al. / FEBS Letters 583 (2009) 1196–1200We have further elucidated by which signaling molecules IL-1ß
induces TIARP/STAMP2 expression. IL-1ß acts through initial inter-
actions with the IL-1R type I [26,27]. Binding of IL-1ß to its recep-
tor leads to activation of IL-1R-associated kinase [28] and
stimulates the downstream signaling protein NFjB by degradation
of inhibitor of jB. The transcription factor NFjB plays a central role
in the transcriptional regulation of inﬂammation-related genes
[29]. We show that pharmacological inhibition of NFjB by parthe-
nolide signiﬁcantly and completely reverses IL-1ß-induced TIARP/
STAMP2 expression but also downregulates basal TIARP/STAMP2
synthesis. These data support NFjB as a principal positive media-
tor of TIARP/STAMP2 gene expression. In addition to NFjB, IL-1ß
activates signaling molecules including Jak2 [30], p42/44 MAP ki-
nase [31], and PI 3-kinase [32]. Since pharmacological inhibition
of Jak2 by AG490 and p44/42 MAP kinase by PD98059 at least par-
tially reverses induction of TIARP/STAMP2 gene expression, these
molecules appear to also mediate some of the positive effect of
IL-1ß. These results are in accordance with previous data from
our group showing that Jak2 plays an important role in basal and
IL-6-induced TIARP/STAMP2 mRNA production [21]. Furthermore,
both Jak2 and p44/42 MAP kinase are involved in GH-stimulated
TIARP/STAMP2 gene expression [20]. It has to be pointed out that
in another set of experiments PD98059 has not signiﬁcantly inﬂu-
enced basal TIARP/STAMP2 [21]. The discrepancies between the ef-
fects of the pharmacological inhibitor on basal TIARP/STAMP2 gene
expression in these studies remain unclear at present but most
probably arise from experiment-to-experiment differences. PI 3-ki-
nase is probably not involved in TIARP/STAMP2 mRNA regulation
by IL-1ß.
Taken together, our data indicate that TIARP/STAMP2 expres-
sion is upregulated in 3T3-L1 cells and hMSC-Ad by IL-1ß. This
upregulation might restrict the proinﬂammatory and insulin resis-
tance-inducing properties of IL-1ß in vitro. Further studies are
needed to determine the role of TIARP/STAMP2 in humans.
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